Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $58.3 million.

  • Tango Therapeutics' Cash & Equivalents rose 9.77% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 9.77%. This contributed to the annual value of $69.5 million for FY2024, which is 0.40% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Cash & Equivalents is $58.3 million, which was up 48.55% from $39.3 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Cash & Equivalents high stood at $207.3 million for Q3 2021, and its period low was $39.3 million during Q2 2025.
  • Its 3-year average for Cash & Equivalents is $58.5 million, with a median of $58.4 million in 2025.
  • Per our database at Business Quant, Tango Therapeutics' Cash & Equivalents spiked by 212,683.58% in 2021 and then slumped by 58.65% in 2022.
  • Tango Therapeutics' Cash & Equivalents (Quarterly) stood at $145.0 million in 2021, then tumbled by 58.65% to $60.0 million in 2022, then climbed by 16.41% to $69.8 million in 2023, then declined by 0.40% to $69.5 million in 2024, then increased by 9.77% to $58.3 million in 2025.
  • Its Cash & Equivalents stands at $58.3 million for Q3 2025, versus $39.3 million for Q2 2025 and $58.4 million for Q1 2025.